| Chief Investigator:
|| Dr Matthew Wallis
|| University of Birmingham
|| Health Technology Assessment (HTA) Programme
| Disease Site:
| Trial Type:
|| Surgery Trial
| UKCRN Study ID: (if applicable)
| Open to new sites?
| Recruitment start date:
|| 4th July 2014
| Anticipated Recruitment end date:
|| July 2020
| CRCTU Trial Management Team:
|| B Team
| Trial E-mail Address:
Ductal carcinoma in situ (DCIS) is an abnormality of the milk ducts in the breast but not in any other breast tissue. DCIS accounts for approximately 20% of breast ‘cancers’ detected by breast screening. Currently, all DCIS is treated by surgery because of concerns that it may become an invasive cancer if left untreated but many experts now believe that some cases of DCIS are unlikely to ever cause any problems in the woman’s lifetime. The LORIS Trial randomises patients with low risk DCIS to standard surgery or to active monitoring with annual mammography.
Please note that the trials team cannot give individual’s clinical advice. Patients and their families should contact their treating physician to discuss trials for which they may be eligible.
Clinical trial protocols are complex technical documents which should only be used for the treatment of subjects taking part in the trial. Patients who are interested in taking part in the trial are advised to talk to their health care professional or refer to CancerHelp website (see the link below).
Investigators please ensure you have R&D approval for this specific version of the protocol before using as a reference.